FinDogFinDog
Wednesday, September 16, 2026Closing data · 4:00 PM ET
English
Log in

ZTS

ZoetisNYSE · Pharmaceuticals · Health Care
Previous close
73.00
Change
−0.43 / −0.59%
FinDog View
Neutral
52-Week Range
71.00 – 149.54
P/E (TTM)
11.5
Forward P/E
10.6
Based on consensus earnings for the next 12 months
Market Cap
$31.9B
1M
+0.04%
S&P 500 −2.41% over same period
Volume / Avg Volume
4.6M / 4.6M
1.00× average

Price History

Closing price · USD1M6M1Y5Y
727476782026-082026-082026-092026-092026-09

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 19.91M6M1Y5Y
10152025302025-092025-122026-032026-062026-09

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis
FY2026 Q2
Quarter ended 2026-06
2026-08-06$2.5B1.87 / 1.87−5.97%Read analysis →
FY2026 Q1
Quarter ended 2026-03
2026-05-07$2.3B1.53 / 1.63−5.13%Pending
FY2025 Q4
Quarter ended 2025-12
2026-02-12—— / —+0.80%Pending
FY2025 Q3
Quarter ended 2025-09
2025-11-04—— / —−3.19%Pending
FY2025 Q2
Quarter ended 2025-06
2025-08-05—— / —+0.26%Pending
FY2025 Q1
Quarter ended 2025-03
2025-05-06—— / —+4.08%Pending

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
P/E is at percentile 0 of its 5-year rangeCheap
5-year range 12.5 – 39.3 · Median 30.2
Last 4 quarters: $3.6B in buybacks + $0 in dividends, 11.43% of market cap combined
P/E (TTM)
11.5
P/B
9.6
P/S
3.2
Dividend Yield
1.64%
Earnings Reaction
Over the last 6 reports, the stock moved ±3.2% on average on the first trading day after, rising 3 times
Most recent −5.97%
Volatility & Correlation
1-year beta 0.57 · Correlation with S&P 500 0.19Low beta
Annualized volatility 38% vs. 13% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
No open-market buys or sells by officers or directors in the last 90 days.
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q22.47−0.2%72.7%—0.690.541.65
FY2026 Q12.26+2.9%71.7%—0.600.291.42
FY2025 Q42.40+3.4%70.7%—0.620.731.42
FY2025 Q32.40+0.5%71.5%—0.720.761.63
FY2025 Q22.47+4.8%73.2%—0.730.461.63
FY2025 Q12.20+0.4%71.9%—0.600.341.34
FY2024 Q42.32+4.7%69.5%—0.580.691.29
FY2024 Q32.39+11.0%70.6%—0.680.781.50
FY2024 Q22.36+8.3%71.7%—0.620.371.37
FY2024 Q12.19+9.5%70.6%—0.600.461.31
FY2023 Q42.21+8.5%67.1%—0.530.701.14
FY2023 Q32.15+7.4%70.3%—0.600.581.29

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView
ZTSZoetis$31.9B11.5−0.2%72.7%+0.04%Neutral
LLYLilly (Eli)$1.07T39.9+47.7%85.8%−3.83%BullishCompare
JNJJohnson & Johnson$644B30.6+6.6%68.2%+1.87%BullishCompare
ABBVAbbVie$464B73.7+10.2%74.7%+4.87%NeutralCompare
MRKMerck & Co.$358B112.2+5.1%73.5%+6.57%NeutralCompare
UNHUnitedHealth Group$337B23.9+0.4%88.1%−5.15%NeutralCompare
TMOThermo Fisher Scientific$240B34.4+10.5%—+10.75%BullishCompare
AMGNAmgen$203B23.3+9.5%72.0%−10.26%NeutralCompare
GILDGilead Sciences$183B—+10.2%79.8%+6.31%NeutralCompare